$0.34

-0.01 (-2.15%)

Weekly Expected Move ±7.8%

$0 $0 $0 $0 $0

NASDAQ · Basic Materials · Agricultural Inputs · Tech Score Sell · Power 29 · $21.6M mcap · 44M float · 0.641% daily turnover · Short 48% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE

38.6 / 100

NoneWeakNarrowWide

Primary source: Switching Costs · ROIC: 0.6% · 5Y Avg: 0.5%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. BIOX has No discernible competitive edge (38.6/100). The business operates without significant structural advantages. The primary source of advantage is Switching Costs. ROIC of 0.6% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

Low

Avg Target

High

Based on 1 analyst ratings (12 mo)

Analyst Recommendations

Strong Buy: 0Buy: 4Hold: 1Sell: 0Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$2.00

Analysts1

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-01-02	Canaccord Genuity	Austin Moeller	$2	$2	-0	+52.7%	$1.31
2025-09-10	Lake Street	Ben Klieve	$13	$5	-8	+142.7%	$2.06
2025-09-10	Canaccord Genuity	—	$12	$2	-10	+21.4%	$2.06
2025-09-09	Oppenheimer	—	$13	$5	-8	+123.2%	$2.24
2024-10-21	Oppenheimer	Kristen Owen	$16	$13	-3	+73.1%	$7.51
2024-09-11	Loop Capital Markets	Ben Klieve	Initiated	$13	—	+56.4%	$8.31
2024-09-11	Lake Street	Ben Klieve	Initiated	$13	—	+50.3%	$8.65
2024-09-11	Canaccord Genuity	Austin Moeller	Initiated	$12	—	+49.6%	$8.36
2024-09-10	Oppenheimer	Kristen Owen	Initiated	$16	—	+85.0%	$8.65
2024-07-02	Roth Capital	Scott Fortune	Initiated	$15	—	+34.8%	$11.13

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

Oct 02, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. BIOX receives an overall rating of C. Strongest factors: P/B (5/5). Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (1/5), P/E (1/5).

Rating Change History

Date	From	To
2026-05-14	C-	C
2026-03-23	C	C-
2026-01-03	C-	C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 15 Grade D

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. BIOX scores highest in Cash Flow (67/100) and lowest in Profitability (9/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

0.21

Distress Zone

Piotroski F-Score

2/9

✗ ✓ ✗ ✓ ✗ ✗ ✗ ✗ ✗

Beneish M-Score

-5.38

Unlikely Manipulator

Ohlson O-Score

-2.67

Bankruptcy prob: 6.5%

Low Risk

Credit Rating

B-

Score: 23.7/100

Trend: Improving

Earnings Quality

—

OCF/NI: -0.28x

Accruals: -48.4%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. BIOX scores 0.21, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. BIOX scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. BIOX's score of -5.38 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. BIOX's implied 6.5% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. BIOX receives an estimated rating of B- (score: 23.7/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

-0.10x

PEG

0.00x

P/S

0.09x

P/B

0.56x

P/FCF

0.44x

P/OCF

0.40x

EV/EBITDA

-12.59x

EV/Revenue

0.96x

EV/EBIT

-7.15x

EV/FCF

3.98x

Earnings Yield

-885.49%

FCF Yield

224.74%

Shareholder Yield

0.82%

Graham Number

—

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. BIOX currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

3.623

NI / EBT

Interest Burden

1.951

EBT / EBIT

EBIT Margin

-0.134

EBIT / Rev

Asset Turnover

0.397

Rev / Assets

Equity Multiplier

3.564

Assets / Equity

ROE

-134.5%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. BIOX's ROE of -134.5% is driven by financial leverage (equity multiplier: 3.56x). Note: high leverage means ROE is amplified by debt rather than operational performance. A tax burden ratio of 3.62 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

—

Price/Value

—

Margin of Safety

—

Premium

—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$0.35

Median 1Y

$0.19

5th Pctile

$0.06

95th Pctile

$0.59

Ann. Volatility

65.1%

25th–75th percentile 5th–95th percentile Median path Historical

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

751

-23.6% YoY

Revenue / Employee

$443,808

Rev: $333,300,000

Profit / Employee

$-68,975

NI: $-51,800,000

SGA / Employee

$117,637

Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
ROE	-12.1%	1.6%	5.2%	-2.1%	-7.4%	-4.4%	-11.0%	8.0%	8.8%	4.9%	7.8%	1.0%	1.1%	0.8%	0.8%	-2.6%	-18.9%	-20.2%	-1.2%	-1.3%	-1.35%
ROA	-2.0%	0.3%	0.9%	-0.4%	-1.6%	-1.2%	-2.9%	2.3%	2.8%	1.7%	2.6%	0.4%	0.4%	0.3%	0.3%	-1.0%	-6.8%	-7.2%	-34.3%	-37.7%	-37.74%
ROIC	-7.3%	4.5%	7.0%	1.6%	-4.3%	-1.2%	-1.2%	8.5%	11.5%	14.7%	10.6%	3.6%	5.3%	5.0%	4.6%	3.0%	0.7%	1.5%	2.5%	0.6%	0.59%
ROCE	13.3%	14.8%	15.1%	17.2%	12.1%	7.9%	4.3%	9.2%	8.4%	6.6%	10.1%	7.2%	7.1%	6.7%	5.1%	2.9%	-6.3%	-6.1%	-12.3%	-16.1%	-16.05%
Gross Margin	40.3%	43.7%	40.4%	34.7%	35.9%	40.5%	35.7%	60.6%	36.8%	37.5%	36.7%	50.7%	33.5%	40.2%	42.2%	39.4%	31.4%	46.0%	35.7%	30.1%	30.10%
Operating Margin	16.9%	15.1%	19.2%	3.1%	9.8%	13.4%	2.3%	32.1%	4.9%	4.6%	12.0%	15.7%	7.6%	2.6%	7.4%	1.6%	-9.3%	10.0%	10.6%	-17.0%	-17.02%
Net Margin	0.8%	1.3%	3.7%	-9.5%	-4.9%	0.4%	-8.6%	30.3%	-1.6%	-4.0%	0.1%	11.0%	-1.2%	-5.9%	0.1%	-2.2%	-64.4%	-9.5%	-2.5%	-32.2%	-32.20%
EBITDA Margin	20.7%	14.0%	21.0%	7.4%	11.1%	15.1%	3.7%	37.1%	5.6%	8.3%	14.1%	23.9%	7.3%	7.9%	11.1%	11.1%	-44.2%	11.6%	9.3%	-8.1%	-8.12%
FCF Margin	-9.7%	-11.8%	-6.2%	-0.3%	-8.1%	-12.2%	-0.8%	-3.0%	-4.8%	6.4%	-0.3%	-3.7%	3.4%	2.0%	-4.4%	5.6%	8.6%	12.5%	26.3%	24.1%	24.12%
OCF Margin	-3.0%	-5.4%	-0.9%	3.0%	-5.3%	-9.3%	2.9%	1.4%	0.6%	12.2%	6.5%	2.2%	9.0%	7.3%	1.4%	12.1%	15.0%	18.6%	28.7%	26.9%	26.93%
ROE 3Y Avg	snapshot only																				-1.31%
ROE 5Y Avg	snapshot only																				-78.20%
ROA 3Y Avg	snapshot only																				-15.99%
ROIC 3Y Avg	snapshot only																				-0.02%
ROIC Economic	snapshot only																				0.57%
Cash ROA	snapshot only																				13.41%
Cash ROIC	snapshot only																				24.58%
CROIC	snapshot only																				22.01%
NOPAT Margin	snapshot only																				0.65%
Pretax Margin	snapshot only																				-26.22%
R&D / Revenue	snapshot only																				4.06%
SGA / Revenue	snapshot only																				19.66%
SBC / Revenue	snapshot only																				0.81%

Valuation

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
P/E Ratio	-84.06	586.44	159.70	-361.07	-87.35	-106.11	-38.71	47.17	44.55	51.63	39.85	275.78	209.42	212.00	165.16	-34.85	-5.17	-1.59	-0.35	-0.11	-0.095
P/S Ratio	2.79	2.48	2.18	1.82	1.91	2.07	1.90	1.76	2.00	1.74	1.93	1.90	1.46	1.12	0.94	0.75	0.85	0.28	0.29	0.11	0.088
P/B Ratio	8.53	7.76	7.12	6.34	4.93	2.96	2.82	2.43	2.81	2.45	2.92	2.70	2.15	1.60	1.24	0.93	1.07	0.36	1.13	0.44	0.556
P/FCF	-28.69	-21.08	-35.29	-524.81	-23.72	-16.93	-232.84	-59.42	-42.00	27.26	-613.02	-50.72	43.58	55.84	-21.44	13.46	9.84	2.25	1.11	0.44	0.445
P/OCF	—	—	—	60.57	—	—	66.33	129.42	324.08	14.27	29.62	84.84	16.28	15.40	67.81	6.19	5.66	1.51	1.02	0.40	0.398
EV/EBITDA	19.41	16.16	14.66	14.38	16.90	18.31	23.99	13.53	16.45	17.14	15.39	19.32	15.28	12.87	13.19	14.91	-74.83	-63.93	-29.85	-12.59	-12.593
EV/Revenue	3.41	3.08	2.72	2.36	2.31	2.58	2.39	2.23	2.47	2.24	2.36	2.40	1.92	1.64	1.57	1.36	1.57	1.07	1.09	0.96	0.961
EV/EBIT	23.46	19.20	17.12	16.96	21.24	23.37	40.07	18.55	23.77	27.14	21.22	29.51	24.03	20.45	22.70	38.48	-19.63	-12.86	-10.92	-7.15	-7.149
EV/FCF	-35.04	-26.20	-44.08	-679.71	-28.67	-21.16	-293.38	-75.09	-51.88	35.18	-749.46	-64.05	57.37	81.61	-35.63	24.43	18.27	8.58	4.14	3.98	3.985
Earnings Yield	-1.2%	0.2%	0.6%	-0.3%	-1.1%	-0.9%	-2.6%	2.1%	2.2%	1.9%	2.5%	0.4%	0.5%	0.5%	0.6%	-2.9%	-19.3%	-63.1%	-2.9%	-8.9%	-8.85%
FCF Yield	-3.5%	-4.7%	-2.8%	-0.2%	-4.2%	-5.9%	-0.4%	-1.7%	-2.4%	3.7%	-0.2%	-2.0%	2.3%	1.8%	-4.7%	7.4%	10.2%	44.4%	90.1%	2.2%	2.25%
PEG Ratio	snapshot only																				0.000
EV/OCF	snapshot only																				3.568
EV/Gross Profit	snapshot only																				2.618
Acquirers Multiple	snapshot only																				116.782
Shareholder Yield	snapshot only																				0.82%

Leverage & Solvency

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Current Ratio	1.26	1.30	1.51	1.16	1.34	1.49	1.36	1.39	1.33	1.27	1.23	1.22	1.24	1.27	1.32	1.02	0.91	0.94	0.90	0.84	0.844
Quick Ratio	0.88	0.76	0.98	0.68	0.77	0.88	0.86	0.89	0.86	0.81	0.84	0.83	0.86	0.87	0.96	0.74	0.65	0.65	0.69	0.67	0.673
Debt/Equity	2.58	2.45	2.25	2.34	1.33	0.93	1.06	0.88	0.86	0.86	0.79	0.81	0.86	0.86	0.92	0.89	1.05	1.07	3.25	3.76	3.762
Net Debt/Equity	1.89	1.89	1.77	1.87	1.03	0.74	0.73	0.64	0.66	0.71	0.65	0.71	0.68	0.74	0.82	0.76	0.92	1.01	3.08	3.53	3.528
Debt/Assets	0.44	0.40	0.40	0.41	0.33	0.32	0.32	0.31	0.31	0.30	0.29	0.31	0.32	0.32	0.34	0.34	0.36	0.36	0.43	0.45	0.453
Debt/EBITDA	4.81	4.11	3.70	4.09	3.78	4.60	7.20	3.86	4.09	4.67	3.40	4.61	4.63	4.74	5.90	7.82	-39.47	-50.26	-23.05	-11.93	-11.928
Net Debt/EBITDA	3.52	3.16	2.92	3.28	2.92	3.66	4.95	2.83	3.13	3.86	2.80	4.02	3.67	4.06	5.26	6.69	-34.52	-47.14	-21.84	-11.19	-11.187
Interest Coverage	1.42	1.92	1.97	1.90	1.68	1.74	0.88	2.31	1.94	1.48	2.51	1.48	1.43	1.41	1.11	0.50	-0.99	-0.91	-0.99	-1.21	-1.210
Equity Multiplier	5.82	6.13	5.58	5.70	4.06	2.90	3.31	2.81	2.74	2.83	2.72	2.67	2.70	2.67	2.70	2.59	2.91	2.95	7.60	8.30	8.301
Cash Ratio	snapshot only																				0.048
Debt Service Coverage	snapshot only																				-0.687
Cash to Debt	snapshot only																				0.062
FCF to Debt	snapshot only																				0.265
Defensive Interval	snapshot only																				638.7 days

Efficiency & Turnover

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Asset Turnover	0.60	0.61	0.68	0.71	0.72	0.63	0.58	0.62	0.63	0.51	0.54	0.53	0.56	0.54	0.49	0.47	0.41	0.41	0.41	0.40	0.397
Inventory Turnover	2.46	1.79	2.15	2.03	2.13	1.85	1.88	1.72	1.79	1.61	1.82	1.90	2.14	2.04	2.09	2.10	1.89	1.82	2.03	2.28	2.282
Receivables Turnover	2.55	2.79	2.70	3.18	3.28	3.27	2.63	3.08	3.11	2.48	2.41	2.42	2.54	2.31	1.91	1.92	1.79	1.80	1.49	1.63	1.629
Payables Turnover	1.87	1.62	1.97	2.09	2.09	1.96	1.86	1.79	1.77	1.65	1.64	1.76	1.85	1.80	1.62	1.66	1.61	1.62	1.61	1.64	1.642
DSO	143	131	135	115	111	111	139	119	117	147	152	151	143	158	191	190	204	203	244	224	224.1 days
DIO	148	204	170	180	171	198	194	213	203	227	201	193	171	179	175	174	193	200	179	160	159.9 days
DPO	196	226	186	175	175	186	197	204	207	222	222	208	197	203	225	220	227	225	227	222	222.2 days
Cash Conversion Cycle	96	108	120	119	108	123	136	127	114	152	130	136	117	134	141	143	171	179	197	162	161.8 days
Fixed Asset Turnover	snapshot only																				3.693
Operating Cycle	snapshot only																				384.0 days
Cash Velocity	snapshot only																				17.697
Capital Intensity	snapshot only																				2.009

Growth (YoY)

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Revenue	19.9%	29.6%	67.9%	77.2%	58.9%	68.4%	42.1%	35.1%	27.7%	5.1%	16.2%	7.1%	10.8%	7.9%	-10.3%	-14.0%	-28.3%	-27.9%	-30.1%	-31.2%	-31.21%
Net Income	-3.0%	-71.6%	1.5%	70.7%	-4.8%	-8.8%	-6.1%	11.0%	3.6%	2.8%	2.1%	-80.3%	-82.8%	-83.0%	-89.4%	-3.7%	-17.8%	-25.2%	-104.0%	-29.4%	-29.43%
EPS	-2.8%	-75.6%	1.5%	72.4%	6.1%	-6.3%	-4.5%	7.5%	2.9%	2.8%	2.1%	-81.4%	-82.2%	-83.0%	-89.3%	-3.9%	-17.1%	-25.0%	-103.5%	-29.0%	-29.04%
FCF	-19.1%	-1.1%	32.8%	97.3%	-31.7%	-74.9%	81.2%	-10.5%	24.7%	1.5%	55.1%	-35.3%	1.8%	-65.9%	-11.5%	2.3%	84.2%	3.5%	5.2%	2.0%	1.98%
EBITDA	11.0%	16.7%	1.1%	71.3%	23.8%	24.7%	-23.7%	35.5%	40.1%	-2.6%	78.9%	-19.2%	-7.1%	5.2%	-30.5%	-36.8%	-1.1%	-1.1%	-1.2%	-1.6%	-1.58%
Op. Income	-1.9%	-3.1%	38.8%	16.5%	3.9%	16.9%	-32.2%	35.5%	35.9%	-9.3%	82.1%	-31.6%	-17.4%	-1.5%	-42.3%	-48.8%	-90.4%	-76.9%	-70.9%	-89.5%	-89.51%
OCF Growth	snapshot only																				53.06%
Asset Growth	snapshot only																				-33.65%
Equity Growth	snapshot only																				-79.33%
Debt Growth	snapshot only																				-12.19%
Shares Change	snapshot only																				1.27%

Growth (CAGR)

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Revenue 3Y	57.9%	41.2%	23.9%	29.3%	27.0%	32.6%	32.9%	33.8%	34.5%	31.9%	40.5%	36.9%	31.0%	24.1%	14.0%	7.6%	0.5%	-6.5%	-10.0%	-14.1%	-14.10%
Revenue 5Y	—	—	—	—	—	—	—	81.9%	51.5%	37.9%	25.7%	25.6%	23.7%	21.5%	19.6%	17.1%	14.1%	12.3%	11.7%	8.7%	8.70%
EPS 3Y	—	-47.2%	62.7%	—	—	—	—	6.6%	47.7%	32.3%	—	—	—	17.3%	-25.4%	—	—	—	—	—	—
EPS 5Y	—	—	—	—	—	—	—	—	36.5%	7.0%	75.7%	—	—	—	—	—	—	—	—	—	—
Net Income 3Y	—	24.1%	71.7%	—	—	—	—	8.1%	77.7%	58.7%	—	—	—	33.8%	-14.7%	—	—	—	—	—	—
Net Income 5Y	—	—	—	—	—	—	—	—	1.5%	93.2%	97.0%	—	—	—	—	—	—	—	—	—	—
EBITDA 3Y	4.6%	2.3%	1.7%	2.1%	52.5%	88.2%	5.6%	26.2%	24.4%	12.3%	43.1%	23.3%	17.2%	8.5%	-1.8%	-11.5%	—	—	—	—	—
EBITDA 5Y	—	—	—	—	—	—	—	—	2.1%	1.1%	92.0%	98.9%	35.8%	46.8%	7.9%	0.5%	—	—	—	—	—
Gross Profit 3Y	58.0%	38.2%	19.3%	22.7%	19.8%	26.0%	24.6%	31.5%	31.4%	27.7%	35.5%	29.6%	25.4%	19.8%	13.4%	6.3%	0.7%	-5.0%	-9.2%	-18.4%	-18.37%
Gross Profit 5Y	—	—	—	—	—	—	—	83.1%	50.9%	35.2%	23.0%	21.6%	19.5%	18.4%	17.3%	13.5%	10.2%	9.0%	7.3%	3.6%	3.62%
Op. Income 3Y	—	—	—	—	1.1%	63.4%	0.7%	20.5%	11.4%	0.9%	19.7%	2.6%	5.3%	1.5%	-10.7%	-22.0%	-52.5%	-40.9%	-32.6%	-66.8%	-66.76%
Op. Income 5Y	—	—	—	—	—	—	—	—	—	—	—	—	59.6%	31.3%	1.4%	-9.3%	-35.8%	-25.2%	-22.0%	-43.4%	-43.42%
FCF 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF 5Y	—	—	—	—	—	—	—	—	—	—	—	—	-10.0%	-22.3%	—	11.1%	91.6%	—	—	—	—
OCF 3Y	—	—	—	-20.9%	—	—	-28.6%	-30.0%	-22.7%	—	—	—	—	—	—	71.2%	—	—	94.2%	1.3%	1.32%
OCF 5Y	—	—	—	—	—	—	—	—	—	—	—	-11.8%	7.0%	-1.9%	-28.7%	23.0%	54.8%	—	—	—	—
Assets 3Y	49.6%	56.5%	58.3%	29.3%	28.8%	49.9%	49.4%	43.7%	40.1%	38.4%	33.2%	32.3%	29.3%	22.3%	21.2%	16.6%	13.8%	-2.2%	-13.7%	-14.5%	-14.48%
Assets 5Y	—	—	—	—	—	—	—	48.4%	47.3%	47.3%	47.2%	29.1%	28.6%	28.8%	26.1%	22.8%	20.7%	18.9%	10.1%	8.0%	7.95%
Equity 3Y	-16.8%	-14.5%	-10.7%	33.5%	39.2%	1.1%	77.9%	89.5%	87.3%	85.0%	70.6%	73.2%	67.0%	61.3%	54.4%	51.8%	27.2%	-2.8%	-34.6%	-40.4%	-40.38%
Book Value 3Y	-64.3%	-63.6%	-15.4%	19.7%	18.2%	75.4%	48.9%	57.3%	55.8%	54.1%	44.7%	44.4%	46.7%	41.4%	35.2%	31.8%	14.3%	-3.6%	-35.2%	-40.5%	-40.55%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Revenue Stability	0.85	0.92	0.72	0.75	0.82	0.82	0.88	0.94	0.96	0.94	0.89	0.90	0.93	0.91	0.86	0.76	0.53	0.39	0.24	0.12	0.124
Earnings Stability	0.00	0.08	0.07	0.05	0.00	0.03	0.07	0.36	0.25	0.22	0.16	0.59	0.45	0.43	0.33	0.00	0.25	0.34	0.37	0.43	0.427
Margin Stability	0.97	0.97	0.95	0.93	0.92	0.92	0.90	0.94	0.93	0.92	0.91	0.92	0.92	0.93	0.93	0.93	0.92	0.92	0.91	0.90	0.904
Rev. Growth Consistency	1.00	1.00	0.50	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.000
Earn. Growth Consistency	0.00	0.00	1.00	0.50	0.00	0.00	0.00	1.00	0.50	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.000
FCF Positive Streak	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0
Earnings Persistence	0.20	0.50	0.20	0.50	0.50	0.20	0.20	0.20	0.20	0.20	0.20	0.50	0.50	0.50	0.50	0.20	0.20	0.20	0.20	0.50	0.500
Earnings Smoothness	—	0.00	—	—	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00	—	—	—	—	—	—
ROE Trend	0.09	0.48	0.30	0.03	-0.04	-0.07	-0.04	0.10	0.14	0.05	0.09	-0.01	0.01	-0.00	0.01	-0.06	-0.24	-0.25	-3.29	-3.92	-3.919
Gross Margin Trend	-0.02	-0.02	-0.04	-0.06	-0.07	-0.07	-0.07	-0.00	0.02	0.01	0.02	-0.02	-0.02	-0.01	0.01	-0.03	-0.02	-0.01	-0.03	-0.02	-0.023
FCF Margin Trend	-0.18	-0.18	-0.07	0.08	-0.04	-0.03	0.10	0.09	0.04	0.18	0.03	-0.02	0.10	0.05	-0.04	0.09	0.09	0.08	0.29	0.23	0.232
Sustainable Growth Rate	—	1.6%	5.2%	—	—	—	—	7.8%	8.7%	4.8%	7.8%	1.0%	1.1%	0.8%	0.8%	—	—	—	—	—	—
Internal Growth Rate	—	0.3%	0.9%	—	—	—	—	2.3%	2.9%	1.7%	2.7%	0.4%	0.4%	0.3%	0.3%	—	—	—	—	—	—

Cash Flow Quality

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
OCF/Net Income	0.90	-12.76	-0.65	-5.96	2.43	4.78	-0.58	0.36	0.14	3.62	1.35	3.25	12.86	13.76	2.44	-5.63	-0.91	-1.05	-0.34	-0.28	-0.283
FCF/OCF	3.24	2.18	7.00	-0.12	1.51	1.31	-0.28	-2.18	-7.72	0.52	-0.05	-1.67	0.37	0.28	-3.16	0.46	0.58	0.67	0.92	0.90	0.896
FCF/Net Income	snapshot only																				-0.254
CapEx/Revenue	6.7%	6.4%	5.3%	3.4%	2.7%	2.9%	3.7%	4.3%	5.4%	5.8%	5.2%	4.3%	4.0%	3.5%	3.3%	3.9%	3.3%	3.0%	2.4%	2.8%	2.81%
CapEx/Depreciation	snapshot only																				0.484
Accruals Ratio	-0.00	0.04	0.02	-0.02	0.02	0.05	-0.05	0.01	0.02	-0.04	-0.01	-0.01	-0.05	-0.04	-0.00	-0.07	-0.13	-0.15	-0.46	-0.48	-0.484
Sloan Accruals	snapshot only																				-0.104
Cash Flow Adequacy	snapshot only																				9.571

Dividends & Buybacks

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	—	0.0%	0.0%	—	—	—	—	1.7%	1.4%	1.9%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—	—	—	—	—
FCF Payout Ratio	—	—	—	—	—	—	—	—	—	1.0%	—	—	0.0%	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Total Payout Ratio	—	3.0%	50.4%	—	—	—	—	17.9%	17.3%	24.3%	6.5%	39.7%	22.6%	11.9%	39.8%	—	—	—	—	—	—
Div. Increase Streak	—	—	—	—	—	—	0	0	0	0	—	—	—	—	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.6%	0.5%	0.3%	0.1%	0.0%	0.0%	0.3%	0.3%	0.4%	0.4%	0.2%	0.1%	0.1%	0.1%	0.2%	0.3%	0.3%	1.0%	0.0%	0.8%	0.82%
Net Buyback Yield	0.6%	0.5%	0.3%	0.1%	0.0%	0.0%	0.3%	0.3%	0.4%	0.4%	0.2%	0.1%	0.1%	0.1%	0.2%	0.3%	0.3%	1.0%	0.0%	0.8%	0.82%
Total Shareholder Return	0.6%	0.5%	0.3%	0.1%	0.0%	0.0%	0.3%	0.4%	0.4%	0.5%	0.2%	0.1%	0.1%	0.1%	0.2%	0.3%	0.3%	1.0%	0.0%	0.8%	0.82%

DuPont Factors

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Tax Burden (NI/EBT)	-0.66	0.05	0.16	-0.07	-0.51	-0.42	-21.13	0.60	0.99	1.73	0.87	0.26	0.32	0.40	-0.64	0.46	0.96	1.01	4.18	3.62	3.623
Interest Burden (EBT/EBIT)	0.35	0.53	0.54	0.50	0.39	0.42	0.04	0.52	0.44	0.24	0.50	0.32	0.27	0.17	-0.13	-1.33	2.13	2.11	2.02	1.95	1.951
EBIT Margin	0.15	0.16	0.16	0.14	0.11	0.11	0.06	0.12	0.10	0.08	0.11	0.08	0.08	0.08	0.07	0.04	-0.08	-0.08	-0.10	-0.13	-0.134
Asset Turnover	0.60	0.61	0.68	0.71	0.72	0.63	0.58	0.62	0.63	0.51	0.54	0.53	0.56	0.54	0.49	0.47	0.41	0.41	0.41	0.40	0.397
Equity Multiplier	6.11	6.37	5.63	5.82	4.67	3.59	3.86	3.47	3.13	2.86	3.00	2.74	2.72	2.75	2.71	2.63	2.80	2.79	3.64	3.56	3.564

Per Share

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
EPS (Diluted TTM)	$-0.17	$0.02	$0.09	$-0.04	$-0.16	$-0.12	$-0.31	$0.25	$0.30	$0.22	$0.34	$0.05	$0.05	$0.04	$0.04	$-0.13	$-0.86	$-0.89	$-3.77	$-3.94	$-3.94
Book Value/Share	$1.65	$1.74	$1.98	$2.15	$2.78	$4.39	$4.27	$4.77	$4.76	$4.61	$4.70	$4.69	$5.20	$4.92	$4.90	$4.92	$4.16	$3.93	$1.16	$1.00	$1.01
Tangible Book/Share	$-0.69	$-0.64	$-0.49	$-0.54	$0.32	$-0.42	$-0.54	$0.07	$0.21	$0.07	$0.24	$0.40	$0.43	$0.35	$0.34	$0.23	$-0.48	$-0.65	$-0.78	$-0.88	$-0.88
Revenue/Share	$5.03	$5.45	$6.49	$7.49	$7.16	$6.30	$6.34	$6.59	$6.68	$6.50	$7.12	$6.67	$7.67	$7.01	$6.45	$6.10	$5.27	$5.02	$4.49	$4.15	$3.87
FCF/Share	$-0.49	$-0.64	$-0.40	$-0.03	$-0.58	$-0.77	$-0.05	$-0.20	$-0.32	$0.41	$-0.02	$-0.25	$0.26	$0.14	$-0.28	$0.34	$0.45	$0.63	$1.18	$1.00	$0.86
OCF/Share	$-0.15	$-0.29	$-0.06	$0.22	$-0.38	$-0.59	$0.18	$0.09	$0.04	$0.79	$0.46	$0.15	$0.69	$0.51	$0.09	$0.74	$0.79	$0.93	$1.29	$1.12	$0.92
Cash/Share	$1.14	$0.98	$0.94	$1.00	$0.84	$0.83	$1.42	$1.12	$0.96	$0.68	$0.65	$0.49	$0.93	$0.61	$0.49	$0.63	$0.55	$0.26	$0.20	$0.23	$0.19
EBITDA/Share	$0.88	$1.04	$1.20	$1.23	$0.98	$0.89	$0.63	$1.08	$1.00	$0.85	$1.09	$0.83	$0.97	$0.89	$0.77	$0.56	$-0.11	$-0.08	$-0.16	$-0.32	$-0.32
Debt/Share	$4.25	$4.26	$4.46	$5.02	$3.70	$4.09	$4.55	$4.18	$4.10	$3.97	$3.70	$3.82	$4.47	$4.24	$4.52	$4.35	$4.38	$4.22	$3.77	$3.77	$3.77
Net Debt/Share	$3.11	$3.28	$3.52	$4.02	$2.86	$3.26	$3.13	$3.06	$3.14	$3.28	$3.06	$3.33	$3.54	$3.63	$4.03	$3.73	$3.83	$3.96	$3.57	$3.54	$3.54

Academic Models

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.207
Altman Z-Prime	snapshot only																				-0.978
Piotroski F-Score	3	3	5	5	4	3	3	7	5	6	7	5	5	6	6	3	2	3	2	2	2
Beneish M-Score	-1.76	-1.72	-1.62	-1.79	-2.31	-1.35	-1.95	-1.98	-1.59	-2.38	-2.29	-2.21	-3.55	-2.64	-2.41	-2.69	-3.20	-3.39	-5.52	-5.38	-5.382
Ohlson O-Score	snapshot only																				-2.671
Net-Net WC	snapshot only																				$-2.81
EVA	snapshot only																				$-27175842.20

Credit

Metric	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Q3'26	Current
Credit Rating	snapshot only																				B-
Credit Score	29.86	31.00	33.75	24.62	34.94	30.81	22.87	35.30	38.39	33.69	43.89	30.82	34.17	31.64	24.91	21.47	25.10	25.20	26.24	23.74	23.743
Credit Grade	snapshot only																				16
Credit Trend	snapshot only																				2.274
Implied Spread (bps)	snapshot only																				900.000
Industry Credit Rank	snapshot only																				15
Sector Credit Rank	snapshot only																				11

BIOX NASDAQ

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet